• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets

by | Jun 28, 2024 | Publications

Pathol Res Pract. 2024 Jun 17;260:155401. doi: 10.1016/j.prp.2024.155401. Online ahead of print. ABSTRACT Phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (Akt) signaling pathways contribute to the development of...

Pembrolizumab plus single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma

by | Jun 28, 2024 | Publications

Lancet Haematol. 2024 Jul;11(7):e473-e475. doi: 10.1016/S2352-3026(24)00168-6. NO ABSTRACT PMID:38937020 | DOI:10.1016/S2352-3026(24)00168-6

Erratum to “Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study”

by | Jun 27, 2024 | Publications

Cancer. 2024 Jun 27. doi: 10.1002/cncr.35464. Online ahead of print. NO ABSTRACT PMID:38935525 | DOI:10.1002/cncr.35464

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma

by | Jun 27, 2024 | Publications

Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433516. doi: 10.1200/EDBK_433516. ABSTRACT This article endeavors to navigate the clinical journey of bispecific antibodies (BsAbs), from elucidating common toxicities and management strategies to examining novel agents and...

Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China

by | Jun 27, 2024 | Publications

Hematology. 2024 Dec;29(1):2367918. doi: 10.1080/16078454.2024.2367918. Epub 2024 Jun 27. ABSTRACT BACKGROUND: The BCL2 interacting protein 3-like (BNIP3L) protein is involved in multiple myeloma (MM) development and progression. This study aims to explore the...

Correlation Analysis between STING Promoter Polymorphism and Susceptibility to Infection after Chemotherapy for Multiple Myeloma

by | Jun 27, 2024 | Publications

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):927-932. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.042. ABSTRACT OBJECTIVE: To investigate the correlation between the stimulator of interferon genes (STING ) promoter polymorphism and the susceptibility to...
« Older Entries
Next Entries »

Recent Content

  • Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
  • Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
  • Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT